about
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationActive chest compression-decompression for cardiopulmonary resuscitationAntiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity[Intravascular lymphomatosis. Report of a case and brief review of the disease][Zoster and postherpetic neuralgia: vaccine prevention is available].Description of liver disease in a cohort of HIV/HBV coinfected patients.[Iatrogenic agitation in elderly patient: prevalence, aetiologies and management].Wrist Actigraphy: A Simple Way to Record Motor Activity in Elderly Patients with Dementia and Apathy or Aberrant Motor Behavior.Predisposing and precipitating factors for delirium in community-dwelling older adults admitted to hospital with this condition: A prospective case series.Management of atrial fibrillationManual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive DeclineKnowledge and use of evidence-based medicine in daily practice by health professionals: a cross-sectional surveyInterleukin-2 therapy in patients with HIV infectionLong term treatment of atrial fibrillation in elderly patients: a decision analysisMixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation[Anticoagulation of older patients: what is new?][Prescribing drugs in the elderly: improvements are necessary][Clinical pharmacology and aging][Drug treatment of agitation in emergency departments: The case of elderly persons. Letter to the article: "Drug management of agitation in emergency departments: Theoretical recommendations and studies of practices"][Anticoagulation use in older patients with atrial fibrillation in a cardio-geriatric unit]Validation of the French version of the Vulnerable Elders Survey-13 (VES-13)[Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?][Hypotensions in the elderly: Clinical and therapeutic features][Heart failure in patients over 80 years old][Gerontological evaluation benefits for very older people with cardiovascular disease][Heart failure in the elderly: A challenge for the health system and a model for the management of chronic diseases]Aging-simulation experience: impact on health professionals' social representationsAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
P50
Q24187110-CBBBEDAE-F45F-4EB0-ABFB-BCF12EBBDA6AQ24198053-3A07FAF6-3D56-437F-85DD-4451F3EC0F40Q33239538-558CBCFA-146B-42C0-9453-7E80C1861F49Q36341724-AD30474C-24B3-4E8C-92A2-C361C47BF08FQ37201673-37C058EE-D16D-4D32-AC2B-B61F15FCC2CBQ40685458-97540044-8065-4C64-A973-4B7572AE04E1Q40759067-79851AC9-652A-4B60-B73E-BB7A6D3BA1D1Q43246288-F340EEDD-E90E-4046-BAD0-ACA219F3336FQ45737858-92EC5797-0D5C-4A98-8060-B5F52BDBCB3DQ47668526-FC65774E-A233-4485-B748-C86F3FD4898CQ51767713-52F05506-A245-4CE5-88F3-019D5EBCEC74Q57249896-32DE9503-4810-4B86-85A1-FCF4007E1B37Q58694931-8F1272E8-3685-4D0A-BBA7-A1FAA3178A05Q64099502-E7485FDF-EA1D-47EC-BF5B-15010B930CE5Q82589457-A7D3E08C-CA1B-4816-9B2E-C9EB133C6C7CQ82712235-304409CA-4437-4124-9A1E-2C68E18CB1CAQ83178529-86B0F929-F65E-44E5-B94A-4BC2A01B0138Q85891917-E99262D5-D841-4763-B33C-F56F7BCBC484Q85895348-147FC56A-3DFC-47E0-AFEA-599ADF556A67Q85920916-5D523D70-6BB0-40D0-AC3D-A4DBFAE270F5Q86517488-BEF19AC8-E82C-4239-9129-3ACC2D0725C9Q89322629-E1EEF992-3EAB-46E1-872A-E528DBAD8F51Q89553762-B72DC257-1C6D-480D-B747-A7EF65673E54Q90350715-80CE1DC3-B7EC-4FC9-ABBD-97FE197D1D6BQ91385625-35261E83-AFD5-4AB5-9FBC-201ED5C0EAA3Q91866111-09B77259-228E-4252-A31C-BE18E351F2BEQ92251773-0B35B892-B75B-4AE5-875E-23B703CCE2E0Q92279840-622C43B3-33A7-41B7-80FD-E9631BF08590Q92819165-E14144BD-EF9E-4950-A326-CF1F4E206370Q93097474-2CF3E7D2-DC2F-4571-A98E-C982D5C5BEA4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmelo Lafuente-Lafuente
@ast
Carmelo Lafuente-Lafuente
@en
Carmelo Lafuente-Lafuente
@es
Carmelo Lafuente-Lafuente
@nl
Carmelo Lafuente-Lafuente
@sl
type
label
Carmelo Lafuente-Lafuente
@ast
Carmelo Lafuente-Lafuente
@en
Carmelo Lafuente-Lafuente
@es
Carmelo Lafuente-Lafuente
@nl
Carmelo Lafuente-Lafuente
@sl
prefLabel
Carmelo Lafuente-Lafuente
@ast
Carmelo Lafuente-Lafuente
@en
Carmelo Lafuente-Lafuente
@es
Carmelo Lafuente-Lafuente
@nl
Carmelo Lafuente-Lafuente
@sl
P106
P1153
12805553000
P21
P31
P496
0000-0002-2475-4670